Buscar

Mostrando ítems 1-4 de 4

Safety and reactogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 viral-like-particle vaccine in older adolescents and young adults.

Moreira Júnior, Edson Duarte; Palefsky, Joel M; Giuliano, Anna R; Goldstone, Stephen; Aranda, Carlos; Jessen, Heiko; Hillman, Richard J; Ferris, Daron G; Coutlee, Francois; Vardas, Eftyhia; Marshall, J. Brooke; Vuocolo, Scott; Haupt, Richard M; Guris, Dalya; Garner, Elizabeth I. O (Taylor & Francis, 2014)

Phase III, randomized controlled trial in girls 9-15 years old to evaluate lot consistency of a novel nine-valent human papillomavirus L1 virus-like particle vaccine.

Luxembourg, Alain; Moreira Junior, Edson Duarte; Samakoses, Rudiwilai; Kim, Kyung-Hyo; Sun, Xiao; Maansson, Roger; Moeller, Erin; Christiano, Susan; Chen, Joshua (Taylor & Francis: STM, Behavioural Science and Public Health Titles, 2016)

A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women

Joura, E. A.; Giuliano, Anna R.; Iversen, O. E.; Bouchard, C.; Mao, C.; Mehlsen, J.; Moreira Júnior, Edson Duarte; Ngan, Y.; Petersen, L. K.; Lazcano‑Ponce, E.; Pitisuttithum, P.; Restrepo, J. A.; Stuart, G.; Woelber, L.; Yang, Y. C.; Cuzick, J.; Garland, S. M.; Huh, W.; Kjaer, S. K.; Bautista, Oliver M.; Chan, I. S. F.; Chen, J.; Gesser, R.; Moeller, E.; Ritter, M.; Vuocolo, S.; Luxembourg, A.; Broad Spectrum HPV Vaccine Study (Massachusetts Medical Society, 2016)

Knowledge of the human papilloma virus and its vaccine in women in a rural area of Querétaro, MéxicoConocimiento del virus del papiloma humano y su vacuna por parte de mujeres de una zona rural de Querétaro, MéxicoConhecimento do vírus do papiloma humano e sua vacina por parte de mulheres de uma zona rural de Querétaro, México

Medina Fernández, Isai Arturo; Gallegos-Torres, Ruth Magdalena; Cervera-Baas, María Eugenia; Cob-Tejeda, Rudy Antonio; Jiménez-Laces, Jenny; Ibarra-Escobedo, Omar (Universidad de Costa Rica, 2016)

Buscar

Filtros

Safety and reactogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 viral-like-particle vaccine in older adolescents and young adults.

Phase III, randomized controlled trial in girls 9-15 years old to evaluate lot consistency of a novel nine-valent human papillomavirus L1 virus-like particle vaccine.

A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women